Breaking News, Collaborations & Alliances

TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC-T Cell Therapies

Partnership enables TCR2 to evaluate multiple allogeneic candidates with novel enhancements and advance a lead candidate in 2022.

Author Image

By: Charlie Sternberg

Associate Editor

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, and Arbor Biotechnologies, a biotechnology company discovering and developing genetic medicines, have entered into a strategic research collaboration and non-exclusive license agreement focused on the further development of a defined set of allogeneic TRuC-T cell therapies.   The collaboration leverages Arbor’s proprietary CRISPR gene-editing ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters